Bo Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bo Wang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Xin Lv
Department of Orthopaedic Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, 030001, China
2 shared publications - Chunyan Du
Laboratory Animal Center of Zhengzhou University Zhengzhou China
1 shared publication - Deliang Shen
Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
1 shared publication - Dongjian Han
Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
1 shared publication Fuhang Wang
Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
1 shared publication- Guofeng Wu
Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, China
1 shared publication
Latest Publications
- Open Access
- 24 November 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (4) , 326
First-in-human transcatheter endocardial alginate-hydrogel implantation for the treatment of heart failure
A 55-year-old male with dilated cardiomyopathy presented with decompensated heart failure (HF). Magnetic resonance imaging (MRI) revealed left ventricular (LV) enlargement (Panel A). The LV ejection fraction (LVEF), end-diastolic volume index (EDVI), and end-systolic volume index (ESVI) were 16%, 234 and 196.8 mL/m2, respectively. The heart team enrolled him in our clinical trial (NCT04781660), designed to evaluate the feasibility and safety of transcatheter endocardial alginate hydrogel implantation (TEAi) for treating HF. The concept of LV augmentation with the alginate hydrogel (AH) uses Laplace's law (Panel B), which increases the LV wall's thickness, reduces the wall stress, and improves cardiac function.1–5 Three-dimension printing techniques were used to evaluate the LV wall thickness (Panels C and D) and to simulate the procedure (Panel F). An 18-F guiding catheter was inserted via the femoral artery and guided crossing the aortic valve under fluoroscopy. Injections were performed with a steerable, dual-lumen needle catheter (Panel E). Transesophageal echocardiography was used to locate the injection sites. The tip of the catheter reached the endocardium (Panel G, arrow), and contrast was injected into the LV wall to identify no leakage or perforation (Panel H). The AH was injected into the myocardium at the mid-LV free wall for 10 sites and 3 ml (Panels I, arrow). Six-month following the procedure, the patient's clinical status was significantly improved (NYHA Class II). MRI confirmed that the LVEF was 22%, with a reduction in EDVI (188.25 mL/m2) and ESVI (146.36 mL/m2). This case demonstrated that TEAi could be effectively and safely performed.
- 24 November 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (4) , 326
Open AccessFirst-in-human transcatheter endocardial alginate-hydrogel implantation for the treatment of heart failure
A 55-year-old male with dilated cardiomyopathy presented with decompensated heart failure (HF). Magnetic resonance imaging (MRI) revealed left ventricular (LV) enlargement (Panel A). The LV ejection fraction (LVEF), end-diastolic volume index (EDVI), and end-systolic volume index (ESVI) were 16%, 234 and 196.8 mL/m2, respectively. The heart team enrolled him in our clinical trial (NCT04781660), designed to evaluate the feasibility and safety of transcatheter endocardial alginate hydrogel implantation (TEAi) for treating HF. The concept of LV augmentation with the alginate hydrogel (AH) uses Laplace's law (Panel B), which increases the LV wall's thickness, reduces the wall stress, and improves cardiac function.1–5 Three-dimension printing techniques were used to evaluate the LV wall thickness (Panels C and D) and to simulate the procedure (Panel F). An 18-F guiding catheter was inserted via the femoral artery and guided crossing the aortic valve under fluoroscopy. Injections were performed with a steerable, dual-lumen needle catheter (Panel E). Transesophageal echocardiography was used to locate the injection sites. The tip of the catheter reached the endocardium (Panel G, arrow), and contrast was injected into the LV wall to identify no leakage or perforation (Panel H). The AH was injected into the myocardium at the mid-LV free wall for 10 sites and 3 ml (Panels I, arrow). Six-month following the procedure, the patient's clinical status was significantly improved (NYHA Class II). MRI confirmed that the LVEF was 22%, with a reduction in EDVI (188.25 mL/m2) and ESVI (146.36 mL/m2). This case demonstrated that TEAi could be effectively and safely performed.
- Open Access
- 3 February 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 830763
A Novel Compound, Tanshinol Borneol Ester, Ameliorates Pressure Overload-Induced Cardiac Hypertrophy by Inhibiting Oxidative Stress via the mTOR/β-TrCP/NRF2 Pathway
Tanshinol borneol ester (DBZ) exerts anti-atherosclerotic and anti-inflammatory effects. However, its effects on cardiac hypertrophy are not well understood. In this work, we investigated the treatment effects and potential mechanisms of DBZ on the hypertrophic heart under oxidative stress and endoplasmic reticulum (ER) stress. A hypertrophic model was established in rats using transverse-aortic constriction (TAC) surgery and in neonatal rat cardiomyocytes (NRCMs) using angiotensin II (Ang II). Our results revealed that DBZ remarkably inhibited oxidative stress and ER stress, blocked autophagy flow, and decreased apoptosisin vivoandin vitrothrough nuclear NRF2 accumulation, and enhanced NRF2 stabilityviaregulating the mTOR/β-TrcP/NRF2 signal pathway. Thus, DBZ may serve as a promising therapeutic for stress-induced cardiac hypertrophy.
- 3 February 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 830763
Open AccessA Novel Compound, Tanshinol Borneol Ester, Ameliorates Pressure Overload-Induced Cardiac Hypertrophy by Inhibiting Oxidative Stress via the mTOR/β-TrCP/NRF2 Pathway
Tanshinol borneol ester (DBZ) exerts anti-atherosclerotic and anti-inflammatory effects. However, its effects on cardiac hypertrophy are not well understood. In this work, we investigated the treatment effects and potential mechanisms of DBZ on the hypertrophic heart under oxidative stress and endoplasmic reticulum (ER) stress. A hypertrophic model was established in rats using transverse-aortic constriction (TAC) surgery and in neonatal rat cardiomyocytes (NRCMs) using angiotensin II (Ang II). Our results revealed that DBZ remarkably inhibited oxidative stress and ER stress, blocked autophagy flow, and decreased apoptosisin vivoandin vitrothrough nuclear NRF2 accumulation, and enhanced NRF2 stabilityviaregulating the mTOR/β-TrcP/NRF2 signal pathway. Thus, DBZ may serve as a promising therapeutic for stress-induced cardiac hypertrophy.
- Open Access
- 29 August 2020
- Published by Oxford University Press (OUP) in Pathogens and Disease
- Vol. 78 (7)
NIK inhibitor impairs chronic periodontitis via suppressing non-canonical NF-κB and osteoclastogenesis
Periodontitis is an inflammatory disease that causes damages to periodontium and alveolar bone. Overactivation and formation of osteoclasts can cause bone destruction, which contributes to periodontitis development. Receptor activator of nuclear factor κB ligand (RANKL)-mediated NF-κB signaling plays an essential role in osteoclasts differentiation. We aimed to study the effects of NIK-SMI1, an NF-κB-inducing kinase (NIK) inhibitor, on the osteoclastogenesis in vitro and periodontitis progression in vivo. A ligature-induced mice model of periodontitis was incorporated to test the potential therapeutic effect of NIK-SMI1 on periodontitis. The target protein and mRNA expression levels were determined by Western blot assay and real-time PCR assay, respectively. We found that the administration of NIK-SMI1 strongly inhibited the RANKL-stimulated non-canonical NF-κB signaling as demonstrated by decreased nuclear p52 expression and activity. Blocking NIK activity also resulted in reduced osteoclasts specific genes expression and enhanced IFN-β expression. NIK-SMI1 treatment resulted in attenuated periodontitis progression and pro-inflammatory cytokines expression in vivo. Our study suggested that NIK-SMI1 exerts beneficial effects on the mitigation of osteoclastogenesis in vitro and periodontitis progression in vivo. Application of NIK-SMI1 may serve as a potential therapeutic approach for periodontitis.
- 29 August 2020
- Published by Oxford University Press (OUP) in Pathogens and Disease
- Vol. 78 (7)
Open AccessNIK inhibitor impairs chronic periodontitis via suppressing non-canonical NF-κB and osteoclastogenesis
Periodontitis is an inflammatory disease that causes damages to periodontium and alveolar bone. Overactivation and formation of osteoclasts can cause bone destruction, which contributes to periodontitis development. Receptor activator of nuclear factor κB ligand (RANKL)-mediated NF-κB signaling plays an essential role in osteoclasts differentiation. We aimed to study the effects of NIK-SMI1, an NF-κB-inducing kinase (NIK) inhibitor, on the osteoclastogenesis in vitro and periodontitis progression in vivo. A ligature-induced mice model of periodontitis was incorporated to test the potential therapeutic effect of NIK-SMI1 on periodontitis. The target protein and mRNA expression levels were determined by Western blot assay and real-time PCR assay, respectively. We found that the administration of NIK-SMI1 strongly inhibited the RANKL-stimulated non-canonical NF-κB signaling as demonstrated by decreased nuclear p52 expression and activity. Blocking NIK activity also resulted in reduced osteoclasts specific genes expression and enhanced IFN-β expression. NIK-SMI1 treatment resulted in attenuated periodontitis progression and pro-inflammatory cytokines expression in vivo. Our study suggested that NIK-SMI1 exerts beneficial effects on the mitigation of osteoclastogenesis in vitro and periodontitis progression in vivo. Application of NIK-SMI1 may serve as a potential therapeutic approach for periodontitis.
- Open Access
- 1 January 2020
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 34
Halofuginone functions as a therapeutic drug for chronic periodontitis in a mouse model
Periodontitis is an inflammatory disease caused by host immune response, resulting in a loss of periodontium and alveolar bone. Immune cells, such as T cells and macrophages, play a critical role in the periodontitis onset. Halofuginone, a natural quinazolinone alkaloid, has been shown to possess anti-fibrosis, anti-cancer, and immunomodulatory properties. However, the effect of halofuginone on periodontitis has never been reported. In this study, a ligature-induced mice model of periodontitis was applied to investigate the potential beneficial effect of halofuginone on periodontitis. We demonstrated that the administration of halofuginone significantly reduced the expression levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) in vivo, and markedly suppressed immune cell infiltration into the infected sites. Furthermore, we also observed that halofuginone treatment blocked the T-helper 17 (Th17) cell differentiation in vivo and in vitro. We demonstrated for the first time that halofuginone alleviated the onset of periodontitis through reducing immune responses.
- 1 January 2020
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
- Vol. 34
Open AccessHalofuginone functions as a therapeutic drug for chronic periodontitis in a mouse model
Periodontitis is an inflammatory disease caused by host immune response, resulting in a loss of periodontium and alveolar bone. Immune cells, such as T cells and macrophages, play a critical role in the periodontitis onset. Halofuginone, a natural quinazolinone alkaloid, has been shown to possess anti-fibrosis, anti-cancer, and immunomodulatory properties. However, the effect of halofuginone on periodontitis has never been reported. In this study, a ligature-induced mice model of periodontitis was applied to investigate the potential beneficial effect of halofuginone on periodontitis. We demonstrated that the administration of halofuginone significantly reduced the expression levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) in vivo, and markedly suppressed immune cell infiltration into the infected sites. Furthermore, we also observed that halofuginone treatment blocked the T-helper 17 (Th17) cell differentiation in vivo and in vitro. We demonstrated for the first time that halofuginone alleviated the onset of periodontitis through reducing immune responses.
- 1 April 2011
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery
- Vol. 69 (4) , 1195-1206
Three-Dimensional Anthropometric Analysis of Chinese Faces and Its Application in Evaluating Facial Deformity
- 1 April 2011
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery
- Vol. 69 (4) , 1195-1206
Three-Dimensional Anthropometric Analysis of Chinese Faces and Its Application in Evaluating Facial Deformity